Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections

J Infect Dis. 1995 Oct;172(4):993-1000. doi: 10.1093/infdis/172.4.993.

Abstract

Risk factors for vancomycin-resistant enterococcal (VRE) bloodstream infection (BSI) were studied at a tertiary-care hospital by comparing 46 patients with VRE-BSI with 46 randomly selected patients with vancomycin-susceptible enterococcal (VSE) BSI. Among patients with an enterococcal BSI, risk factors for mortality were determined. Independent risk factors for VRE-BSI were increasing APACHE II score (odds ratio [OR], 2.3/5-point increase; 95% confidence interval [CI], 1.4-3.9), receipt of vancomycin (OR, 11; 95% CI, 5.5-21), or diagnosis of hematologic malignancy (OR, 8.4; 95% CI, 3.9-18). After controlling for APACHE II score and gender, patients with VRE- versus VSE-BSI did not have a significantly elevated risk of mortality (OR, 3.3; 95% CI, 0.7-15). Five of 28 VRE blood isolates typed using pulsed-field gel electrophoresis had identical banding patterns. These data suggest that increasing severity of illness, underlying disease, and receipt of vancomycin are major risk factors for VRE-BSI.

MeSH terms

  • APACHE
  • Age Factors
  • Aged
  • Anti-Bacterial Agents / pharmacology*
  • Case-Control Studies
  • Cross Infection / blood
  • Cross Infection / epidemiology*
  • Cross Infection / mortality
  • Drug Resistance, Microbial
  • Enterococcus / classification
  • Enterococcus / pathogenicity*
  • Female
  • Gram-Positive Bacterial Infections / blood
  • Gram-Positive Bacterial Infections / epidemiology*
  • Gram-Positive Bacterial Infections / mortality
  • Humans
  • Inpatients
  • Multivariate Analysis
  • New York City / epidemiology
  • Patient Compliance
  • Patient Isolation
  • Regression Analysis
  • Time Factors
  • Vancomycin / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Vancomycin